Last updated: February 27, 2026
What Is the Product With NDC 50268-0052?
NDC 50268-0052 corresponds to Blenrep (belantamab mafodotin), a monoclonal antibody approved by the FDA in August 2020 for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapies. It targets B-cell maturation antigen (BCMA), a protein expressed on malignant plasma cells.
Market Size and Trends
Current Market Landscape
- The multiple myeloma market is valued at approximately $13 billion in 2022, with a projected compound annual growth rate (CAGR) of 8%.
- Blenrep addresses a heavily relapsed patient segment, representing an estimated 15-20% of the multiple myeloma population, roughly 30,000-40,000 patients in the U.S. (based on incidence rates and treatment patterns).
- The drug's market penetration remains limited due to safety concerns (ocular toxicity) and competition from newer agents such as CAR-T therapies (ide-cel and cilta-cel).
Competitive Environment
- Other therapies for relapsed/refractory multiple myeloma include belantamab mafodotin's competitors like CAR-T therapies (ide-cel, cilta-cel) and bispecific antibodies.
- The market share distribution shifts based on approval timing, efficacy, safety profile, and reimbursement landscape.
Price History and Current Pricing
- The list price for Blenrep in the U.S. is approximately $13,350 per dose, with an average treatment course involving 4-6 doses, resulting in a total treatment cost of approximately $54,600-$80,100.
- Insurance coverage and patient assistance programs impact net pricing.
Price Projections and Impacts
Short-Term Outlook (Next 1-2 Years)
- Minimal price fluctuation expected due to established list price, with potential slight decreases driven by payer negotiations.
- No significant price reduction anticipated without new safety data, additional indications, or approval of competitors.
Medium to Long-Term Outlook (3-5 Years)
- Price adjustments could occur in response to market competition, especially if CAR-T therapies demonstrate superior efficacy or safety profiles, which could diminish Blenrep's market share.
- Potential introduction of biosimilars is unlikely due to the complexity of the drug’s conjugate structure.
Influencing Factors
| Factor |
Impact |
Details |
| Market Penetration |
Downward pressure |
As new therapies enter, sales volume could decrease. |
| Safety Profile |
Price stability |
Ocular toxicity management might influence pricing negotiations. |
| Reimbursement Policies |
Price stabilization |
Favorable coverage can preserve current prices. |
| New Indications |
Price increase |
Expansion into earlier lines or additional indications could justify premium pricing. |
Regulatory and Reimbursement Dynamics
- The FDA approved Blenrep based on DREAMM-2 trial results demonstrating an overall response rate (ORR) of 31%.
- Payer policies require post-marketing safety data, which could influence reimbursement and net pricing.
Key Takeaways
- NDC 50268-0052 (Blenrep) is a targeted therapy for a niche within a large and growing multiple myeloma market.
- The current list price remains around $13,350 per dose, with total treatment costs between $54,600 and $80,100.
- Market share is constrained by safety concerns and competition from CAR-T and bispecific therapies.
- Price projections suggest stability for the next 1-2 years, with possible declines occurring after that due to increased competition.
- Factors such as safety profile, market penetration, and regulatory decisions will influence future pricing and market dynamics.
FAQs
1. What is the primary mechanism of action for Blenrep? Belantamab mafodotin targets BCMA on malignant plasma cells, delivering a cytotoxic payload to induce cell death.
2. How does the safety profile affect pricing? Ocular toxicity may limit dosing and adherence, impacting reimbursement negotiations and coverage decisions.
3. Are biosimilars likely for Blenrep? Due to its complex antibody-drug conjugate structure, biosimilar development is unlikely in the near term.
4. What competitive therapies impact Blenrep's market share? CAR-T therapies (ide-cel, cilta-cel) and bispecific antibodies (Teclistamab) are notable competitors in relapsed myeloma.
5. How could new indications influence the market? Approved expansion into earlier lines or additional patient populations could increase demand and permit higher pricing.
References
[1] U.S. Food and Drug Administration. (2020). FDA approves belantamab mafodotin-blmf for multiple myeloma. Retrieved from https://www.fda.gov
[2] IQVIA. (2022). U.S. multiple myeloma market analysis. IQVIA Institute.
[3] Bloomberg. (2023). Oncology drug pricing trends. Retrieved from https://www.bloomberg.com
